SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 102.90+1.3%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ANGELIQUE LEE who wrote ()2/13/2000 5:28:00 PM
From: sim1  Read Replies (1) of 3202
 
From Signals Magazine - "Big Pharma's Squeeze Play"

Big pharma's merger mania has taken on a new sense of urgency, as already-huge companies strive to achieve ever more massive proportions. Driven by the need to develop a new generation of blockbuster drugs, they're creating gargantuan R&D budgets to support hordes of research scientists. The new drug targets are there, too -- thousands upon thousands of them, thanks to the human genome sequencing effort. But while pharmaceutical companies are amassing the vast resources necessary to undertake this very pricey approach to drug development, the ability to turn these targets into approved drugs remains a challenge -- one that requires the technologies, services and expertise of the genomics companies. Not only should these ongoing alliances survive the consolidation, but also new deals could be far richer. Will the hundreds of other biotech alliances fare as well? <snip>

signalsmag.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News